Sandbox/22: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{====Stage C==== | |||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | {{familytree | A01 | |A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Treatment goal''':<br> | ||
❑ <br> ❑ <br>❑ <br>❑ <br> | ❑ </div>}} | ||
{{familytree | |!| | |}} | |||
{{familytree | B02 | |B02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> | |||
❑ [[Acute decompensated heart failure resident survival guide#Diuretic Therapy|Diuretic therapy]] for fluid retention | |||
❑ [[ACE inhibitors]] ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<br> | |||
❑ [[Angiotensin II receptor antagonist|Angiotensin II receptor blocker]] ([[ARBs]]), use in:<br> | |||
:❑ [[ACE inhibitor]] intolerant patients with reduced LVEF ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<br> | |||
:❑ As an alternative to [[ACE inhibitor]] as first line therapy ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence A]])<br> | |||
❑ [[Beta blockers]] (for all stable patients) ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<br> | |||
❑ [[Aldosterone antagonist|Aldosterone receptor antagonist]]<br> | |||
:❑ NYHA class II-IV with LVEF ≤ 35% ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<br> | |||
❑ [[Hydralazine]] and [[isosorbide dinitrate]]<br> | |||
:❑ <br> | |||
:❑ <br> | |||
❑ [[Digoxin]] <br> | |||
:❑ <br> | |||
:❑ [[Omega-3 fatty acid]] | |||
❑ [[Implantable cardioverter defibrillator]] (ICD) to prevent sudden death in: <br> | |||
:❑ <br> | |||
:❑ <br> | |||
:❑ <br> | |||
:❑ <br> | |||
❑ [[Cardiac resynchronization therapy]] (CRT)<br> | |||
:❑ <br> | |||
:❑ <br> | |||
:❑ <br> | |||
:❑ <br> | |||
</div>}} | </div>}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 19:38, 1 April 2014
{====Stage C====
Treatment goal: ❑ | |||||||||
❑ Diuretic therapy for fluid retention
❑ ACE inhibitors (Class I, level of evidence A)
❑ Beta blockers (for all stable patients) (Class I, level of evidence A)
❑ Hydralazine and isosorbide dinitrate
❑ Digoxin ❑ Implantable cardioverter defibrillator (ICD) to prevent sudden death in:
❑ Cardiac resynchronization therapy (CRT)
| |||||||||